作者: Emmanuel Nony , Christophe de Romeuf , Philippe Klein , Christine Gaucher , Sylvie Jorieux
DOI:
关键词:
摘要: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said bringing about a high ADCC activity as well secretion cytokines and interleukins, for treating underpopulations so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote FCGR3A-158V/F heterozygote polymorphism.